Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.

Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

Overcoming Barriers for Latinos on Cancer Clinical Trials.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Proactive steps to optimize the management of polycythemia vera and myelofibrosis.

Validation of a commercial antibody to detect endogenous human nicastrin by immunoblot.

Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.

Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.

Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.